BRONCHODILATORS → SHORT-ACTING MUSCARINIC ANTAGONIST (SAMA) → Atrovent® HFA

Atrovent® HFA

BRONCHODILATORS

SHORT-ACTING MUSCARINIC ANTAGONIST (SAMA)

  • Class

    • Short-acting muscarinic antagonist (SAMA)

  • Active ingredient

    • Ipratropium bromide

  • Device

  • Age

    • 18 +

  • Typical use

    • Asthma
      severe exacerbation in the ER

    Asthma management principles

    • COPD
      exacerbation in the ER

    COPD management principles

  • Marketed strength

    • 20 mcg

  • Number of doses

    • 200 doses

  • Dose indicator

    • No

  • Usual adult dosage

    • 2 inh q 1-4h PRN 
      Maximum daily dose: 12 inh (240 mcg)

  • Usual pediatric dosage

    • -

  • Required inspiratory flow

    • < 30 L/min 
      Zero internal resistance (R0)

    Inspiratory flows

  • Public coverage

    • All provinces | Open/Regular Benefit

  • Advantages

    • Suitable for low inspiratory flows
    • Low cost
    • No synchronism required with a spacer

  • Disadvantages

    • Short duration of action
    • M2 receptor blockade which may cause bronchoconstriction
    • Contain greenhouse gases
    • Impossible to know when empty
    Side Effects

Product monograph

Download

Search for other inhalers

Explore the full list